Galderma says ARCADIA extension data show Nemluvio sustains atopic dermatitis gains through three years
Galderma flagged new three-year ARCADIA extension results for Nemluvio in moderate-to-severe atopic dermatitis, scheduled for presentation at EADV 2026. Data indicate durable disease control with sustained improvements in skin symptoms, itch, sleep disruption, and quality of life. Treatment remained well-tolerated over